Development of a prediction model for radiotherapy response among patients with head and neck squamous cell carcinoma based on the tumor immune microenvironment and hypoxia signature.
gene signature
head and neck squamous cell carcinoma
hypoxia
immune
radiosensitivity
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
26
02
2022
received:
04
02
2022
accepted:
18
04
2022
pubmed:
5
5
2022
medline:
15
12
2022
entrez:
4
5
2022
Statut:
ppublish
Résumé
The immune system and hypoxia are major factors influencing radiosensitivity in patients with different cancer types. This study aimed at developing a model to predict radiotherapy response in patients with head and neck squamous cell carcinoma (HNSCC) based on the tumor immune microenvironment and hypoxia signature. We first evaluated the hypoxia status and tumor immune microenvironment in the Cancer Genome Atlas (TCGA) cohort by using transcriptomic data. Differentially expressed genes (DEGs) were identified between the "high immunity and low hypoxia" and "low immunity and high hypoxia" groups and those DEGs significantly associated with disease-specific survival in the univariate Cox regression analysis were selected as the prognostic DEGs. We selected the immune hypoxia-related genes (IHRGs) by intersecting prognostic DEGs with immune and hypoxia gene sets. We used the IHRGs to train a multivariate Cox regression model in the TCGA cohort, based on which we calculated the IHRG prognostic index (IHRGPI) for each patient and validated its efficacy in predicting radiotherapy response in the Gene Expression Omnibus cohorts. Furthermore, we explored potential mechanisms and effective combinational treatment strategies for different IHRGPI groups. Five IHRGs were used to construct the IHRGPI, which was used to dichotomize the cohorts. The patients with lower IHRGPI showed a better radiotherapy response across different cohorts and endpoints, including overall survival, progression-free survival, and recurrence-free survival (p < 0.05). Patients with higher IHRGPI showed greater hypoxia and lesser immune cell infiltration. A lower IHRGPI indicated a better immunotherapy response, while a higher IHRGPI indicated a better chemotherapy response. IHRGPI is promising for predicting radiotherapy response and guiding combinational treatment strategies in patients with HNSCC.
Identifiants
pubmed: 35505641
doi: 10.1002/cam4.4791
pmc: PMC9741991
doi:
Substances chimiques
Penicillins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4673-4687Subventions
Organisme : Key-Area Research and Development Program of Guangdong Province
ID : 2019B020230002
Organisme : Medical Science and Technology Research Fund of Guangdong Province
ID : A2019418
Organisme : 111 Project
Organisme : Overseas Expertise Introduction Project for Discipline Innovation
ID : B14035
Organisme : Natural Science Foundation of Guangdong Province
ID : 2017A030312003
Organisme : Research and Development
Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Front Oncol. 2021 Apr 15;11:591386
pubmed: 33937018
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Br J Cancer. 2021 Jan;124(2):359-367
pubmed: 32929195
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):435-41
pubmed: 11173138
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Sci Rep. 2017 Jan 23;7:41138
pubmed: 28112237
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Cancer Res Treat. 2018 Jul;50(3):658-669
pubmed: 28701032
Curr Mol Med. 2009 May;9(4):442-58
pubmed: 19519402
PLoS One. 2013;8(2):e56823
pubmed: 23451093
Nat Med. 2004 May;10(5):502-9
pubmed: 15098027
Oral Oncol. 2018 Nov;86:225-233
pubmed: 30409305
BMC Med. 2017 Sep 1;15(1):165
pubmed: 28859688
Front Pharmacol. 2021 Apr 15;12:626972
pubmed: 33935718
Cancers (Basel). 2019 Jun 20;11(6):
pubmed: 31226866
Br J Radiol. 2014 Mar;87(1035):20130686
pubmed: 24338942
Cancer Lett. 2021 May 1;505:1-12
pubmed: 33610729
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nucleic Acids Res. 2019 Jul 2;47(W1):W212-W224
pubmed: 31114921
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Semin Thromb Hemost. 2019 Jun;45(4):385-395
pubmed: 31096306
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Oncotarget. 2016 Aug 30;7(35):57351-57366
pubmed: 27385000
Mol Cell. 2008 Feb 29;29(4):488-98
pubmed: 18313386
Clin Cancer Res. 2018 Mar 15;24(6):1364-1374
pubmed: 29298797
Cancer Lett. 2018 Jun 1;423:60-70
pubmed: 29526801
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
PLoS One. 2014 Sep 17;9(9):e107468
pubmed: 25229481
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Cancer Res. 2007 Apr 1;67(7):3441-9
pubmed: 17409455
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Hematol Oncol. 2021 Mar 19;14(1):45
pubmed: 33741032
N Engl J Med. 2011 Aug 11;365(6):537-47
pubmed: 21830968
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
Radiat Oncol J. 2020 Jun;38(2):99-108
pubmed: 33012153
Cancer Med. 2022 Dec;11(23):4673-4687
pubmed: 35505641
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Int J Radiat Biol. 1989 Dec;56(6):1045-8
pubmed: 2574214
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Front Genet. 2020 Aug 18;11:960
pubmed: 33014019
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96
pubmed: 19735873
Semin Radiat Oncol. 2013 Oct;23(4):281-7
pubmed: 24012342
Nat Commun. 2013;4:2612
pubmed: 24113773